Meet the lung researcher: Andrew
Dr Andrew Durham at Imperial College London is studying the prevention of fatal lung fibrosis (scarring) in COPD and other lung diseases
Why do we need this study?
We have previously tested a new drug, JQ1, on fibroblasts from patients with ILD. The drug stopped the fibroblasts dividing and producing the proteins that form the scar tissue. The result was that the fibroblast cells came to resemble, more closely, cells from healthy patients. We now want to test JQ1 on fibroblasts from people with COPD.
What is involved?
Using tissue samples with fibroblasts from people with COPD, we will test JQ1. Our aim is to see whether the drug can have the same effect on the COPD fibroblasts that it does on ILD fibroblasts.
What do we hope to achieve?
If our findings show that JQ1 can turn off the damaging fibroblasts in both ILD and COPD, this may offer hope of finding a way to stop lung fibrosis. This would involve testing new drugs to target the fibroblasts, in animal models and, later, in clinical trials with patients. Ultimately, our hope is to improve our understanding of fibrosis and the treatment of lung and other diseases.
Leading the fight against lung disease through research
We have a long history of research into respiratory disease.
The BLF helped me present my research
John Lowe says support helps scientists to research lung disease.